<unk>  is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of the interleukin-23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 plays a critical role in modulating inflammatory and immune responses. Recent research has found the IL-23/Th17 pathway to be crucial for the pathogenic mechanisms of psoriasis, with IL-23 considered the “master cytokine” since it acts at the top of the inflammatory pathway, activating the proliferation of pathogenic Th17 cells and subsequent production of proinflammatory cytokines, including IL-17. Structurally, IL-23 is a heterodimer with two subunits, p19 and p40. The p40 subunit is also shared with IL-12, a cytokine that is involved in the immune response. Treatments targeting the p40 subunit block both IL-23 and IL-12 and have been associated with an increased risk of infections.<unk>  binds only to the p19 subunit of IL-23. Through this specific blockage,<unk>  inhibits the release of proinflammatory cytokines and chemokines that mediate epidermal hyperplasia, keratinocyte immune activation, and tissue inflammation inherent in psoriasis.
Tildrakizumab
Brolucizumab
Risankizumab
Mogamulizumab
Etaracizumab
Caplacizumab
Ixekizumab
Crizanlizumab